First 'crowd-sourcing' drug development programme gets underway in MS
This article was originally published in Scrip
Executive Summary
Transparency Life Sciences (TLS), which claims to be the world's first drug development company based on open innovation, has signed an exclusive option agreement with Stanford University for the use of lisinopril as a treatment for multiple sclerosis (MS).